BR112012019498A2 - composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida. - Google Patents

composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida.

Info

Publication number
BR112012019498A2
BR112012019498A2 BR112012019498A BR112012019498A BR112012019498A2 BR 112012019498 A2 BR112012019498 A2 BR 112012019498A2 BR 112012019498 A BR112012019498 A BR 112012019498A BR 112012019498 A BR112012019498 A BR 112012019498A BR 112012019498 A2 BR112012019498 A2 BR 112012019498A2
Authority
BR
Brazil
Prior art keywords
lactase
lactose
composition
dosage form
solid dosage
Prior art date
Application number
BR112012019498A
Other languages
English (en)
Inventor
Henry Wyrobnik Daniel
Harry Wyrobnik Isaac
Original Assignee
Vitacare Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42244285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019498(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitacare Gmbh & Co Kg filed Critical Vitacare Gmbh & Co Kg
Publication of BR112012019498A2 publication Critical patent/BR112012019498A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)

Abstract

composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida. a invenção refere-se a uma composição para uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose, em que a composição é uma forma de dosagem sólida de produtos não lácteos compreendendo: (a) uma lactase; e (b) um ou mais micro-organismos que contêm lactase e/ou que produzem lactase selecionados de lactobacillus delbruekii ssp bulgaricus e steptococcus termophilus; em que a lactase (a) é outra que não uma lactase derivada do dito um ou mais micro-organismo (b); e em que o um ou mais micro-organismo que produzem lactase e /ou contêm lactase (b) estão na forma seca. também são providas cápsula não revestida e composições em comprimido contendo a lactase e os micro-organismos que produzem lactase e/ou lactase.
BR112012019498A 2010-02-05 2011-02-04 composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida. BR112012019498A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE102010007142 2010-02-05
DE102010007289 2010-02-08
DE102010007304 2010-02-08
DE102010008083 2010-02-15
US33876310P 2010-02-24 2010-02-24
DE102010009582A DE102010009582A1 (de) 2010-02-05 2010-02-26 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
EP10004161A EP2353600A1 (de) 2010-02-05 2010-04-20 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
PCT/EP2011/000510 WO2011095339A1 (en) 2010-02-05 2011-02-04 A composition for use in the therapy of lactose intolerance or conditions arising from lactase deficiency

Publications (1)

Publication Number Publication Date
BR112012019498A2 true BR112012019498A2 (pt) 2018-03-27

Family

ID=42244285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019498A BR112012019498A2 (pt) 2010-02-05 2011-02-04 composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida.

Country Status (14)

Country Link
US (2) US20120308524A1 (pt)
EP (2) EP2353600A1 (pt)
JP (1) JP2013518842A (pt)
CN (2) CN107375912A (pt)
AU (1) AU2011212675B2 (pt)
BR (1) BR112012019498A2 (pt)
CA (1) CA2826611C (pt)
DE (1) DE102010009582A1 (pt)
DK (1) DK2528611T3 (pt)
ES (1) ES2471877T3 (pt)
PL (1) PL2528611T3 (pt)
PT (1) PT2528611E (pt)
RU (1) RU2012137786A (pt)
WO (1) WO2011095339A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010009582A1 (de) 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
JP6103956B2 (ja) * 2013-01-24 2017-03-29 サッポロビール株式会社 乳酒の製造方法及び乳酒
CN114832092A (zh) * 2013-07-12 2022-08-02 艾尔牛奶有限公司 β-酪蛋白A2和减轻或预防乳糖不耐受症状
SI24570A (sl) 2013-12-23 2015-06-30 Medis D.O.O. Novi sevi rodu Lactobacillus in njihova uporaba
RU2684099C1 (ru) * 2017-03-16 2019-04-04 Государственное бюджетное учреждение здравоохранения города Москвы "Московский клинический научно-практический центр имени А.С. Логинова Департамента здравоохранения города Москвы" Способ лечения лактазной недостаточности у взрослых
CN112704116A (zh) * 2020-12-10 2021-04-27 红原牦牛乳业有限责任公司 一种低乳糖a2牦牛奶分离纯化系统以及分离纯化方法
WO2022243052A1 (en) * 2021-05-18 2022-11-24 Chr. Hansen A/S Method of producing fermented milk products with improved texture and reduced post-acidification
CN114304271B (zh) * 2022-03-04 2022-05-24 山东福乐维康生物科技有限公司 一种适于乳糖不耐症人群的益生菌发酵牛奶及其制备方法
WO2024013211A1 (en) * 2022-07-12 2024-01-18 Novozymes A/S Method for providing relief from lactose induced abdominal discomfort

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4034115A (en) 1975-07-29 1977-07-05 Roberts James Gorden Multi-curdled milk product and the process for the preparation thereof
DE2725731C2 (de) * 1977-06-07 1986-10-09 James Gordon Clearwater Fla. Roberts Verfahren zur Herstellung eines Nahrungsmittels auf Milchbasis
US6428786B1 (en) 1993-09-28 2002-08-06 Mcneil-Ppc, Inc. Composition and method for lactose hydrolysis
IT1270216B (it) 1994-06-14 1997-04-29 Recordati Chem Pharm Metodo di stabilizzazione di composti biologicamente attivi mediante microgranuli ricoperti sospendibili in fluidi alimentari
FR2723963B1 (fr) 1994-08-31 1997-01-17 Gervais Danone Co Preparation de produits fermentes par streptococcus thermophilus, enrichis en galacto-oligosaccharides et en beta-galactosidase
US6562338B2 (en) 1995-06-06 2003-05-13 Mcneil-Ppc, Inc. Composition and method for lactose hydrolysis
US6562339B2 (en) 1995-10-17 2003-05-13 Mcneil-Ppc, Inc. Composition and method for lactose hydrolysis
US6008027A (en) * 1997-07-17 1999-12-28 Langner; Bruce J. Enteric polymer coated capsule containing dried bacterial culture for supplying lactase
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
PT1112002E (pt) 1998-09-08 2002-11-29 Nestle Sa Leite em po para animais de estimacao
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
WO2004089290A2 (en) * 2003-04-02 2004-10-21 Pharmachem Laboratories, Inc. Novel probiotic compositions and methods of using the same
US20080126195A1 (en) * 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
US20060068075A1 (en) * 2004-09-30 2006-03-30 Fultz Jerry L Flavored yogurt products and methods of making same
RU2292145C2 (ru) * 2004-11-29 2007-01-27 Федеральное государственное образовательное учреждение высшего профессионального образования Омский Государственный Аграрный Университет Композиция для производства кисломолочного профилактического продукта
US9351500B2 (en) * 2006-02-01 2016-05-31 General Mills, Inc. Aerated milk compositions
JP5054687B2 (ja) * 2006-06-26 2012-10-24 一般財団法人糧食研究会 乳糖不耐症を改善するための乳酸菌
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
US20080213320A1 (en) * 2007-03-01 2008-09-04 Jeremy B. Eisenstein Compositions for treatment of gastro-esophageal reflux disorders
US20080260708A1 (en) * 2007-04-19 2008-10-23 Hall Mickey A Methods and related systems and formulations to normalize and improve human body chemistry and healing ability
US8236297B2 (en) 2007-10-11 2012-08-07 Kenneth Manzo Method of treating lactose intolerance using genetically engineered bacteria
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
EP2209886A1 (en) 2007-10-30 2010-07-28 Danisco A/S Growth medium for lactic acid bacteria
CN101209346A (zh) * 2007-12-21 2008-07-02 广东众生药业股份有限公司 治疗消化不良的药物及其制备方法
CN101518283B (zh) * 2009-04-13 2012-06-06 天津科技大学 一种酸奶
DE102010009582A1 (de) 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz

Also Published As

Publication number Publication date
US20120308524A1 (en) 2012-12-06
US11166992B2 (en) 2021-11-09
DK2528611T3 (da) 2014-06-23
US20150328267A1 (en) 2015-11-19
ES2471877T3 (es) 2014-06-27
CA2826611C (en) 2019-01-08
EP2528611B1 (en) 2014-03-19
CA2826611A1 (en) 2011-08-11
AU2011212675A1 (en) 2012-09-20
EP2353600A1 (de) 2011-08-10
PT2528611E (pt) 2014-06-24
WO2011095339A1 (en) 2011-08-11
PL2528611T3 (pl) 2014-08-29
EP2528611A1 (en) 2012-12-05
CN102946892A (zh) 2013-02-27
RU2012137786A (ru) 2014-03-10
AU2011212675B2 (en) 2015-05-28
JP2013518842A (ja) 2013-05-23
CN107375912A (zh) 2017-11-24
DE102010009582A1 (de) 2011-08-11

Similar Documents

Publication Publication Date Title
BR112012019498A2 (pt) composição para o uso na terapia de intolerância à lactose ou condições que surgem da deficiência de lactose e forma de dosagem sólida.
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
BR112018074795A2 (pt) novo uso médico de probióticos
BR112014030202A2 (pt) microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MY161088A (en) Agonists of gpr40
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112017010475A2 (pt) cepas de lactobacillus ou bifidobacterium para manter homeostase
BR112018075625A2 (pt) composição nutricional compreendendo um probiótico para a prevenção e/ou tratamento de distúrbios de ansiedade e condições relacionadas em um mamífero
WO2014170389A8 (en) Enhanced adoptive cell therapy
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112014025469A2 (pt) uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias
BR112013005679A2 (pt) imidazopiridazinas substituídas
CO6700848A2 (es) Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad
BR112013028705A2 (pt) cepas bacterianas probióticas e composição simbiótica contendo as mesmas destinadas a alimentos para lactentes
BR112012019190A2 (pt) composições de cuidado oral.
BR112015006424A2 (pt) grãos fundidos de sub-óxidos de titânio e produtos cerâmicos comportando tais grãos
CL2013001314A1 (es) Composicion de yogur de consistencia espesa que comprende microorganismos probióticos no replicantes.
BR112013011184A2 (pt) composições e métodos para tratamento de mielofibrose
BR112013010881A2 (pt) preparações de bebida de iogurte contendo micro-organismos probióticos não replicantes
BR112013025047A2 (pt) composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
BR112018009192A8 (pt) composição de prebiótico e probiótico combinados
BR112012028090A2 (pt) comprimidos de meloxicam de baixa concentração

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]